Valeant leads the way in steep price increase of skin drugs
New York
TWO drugs sold by Valeant Pharmaceuticals International to treat cancer-related skin conditions increased in price by about 1,700 per cent over the last six years, according to a newly published survey that found big increases in the cost of dermatology drugs across the board.
Overall, retail prices of 19 brand-name dermatology drugs from various manufacturers, for acne, infections and other conditions, quintupled from 2009 to this year. Even some generic drugs almost quadrupled in price, according to the study, which was published on Wednesday by the journal JAMA Dermatology.
BT is now on Telegram!
For daily updates on weekdays and specially selected content for the weekend. Subscribe to t.me/BizTimes
Consumer & Healthcare
‘Extreme’ climate blamed for world’s worst wine harvest in 62 years
Sheng Siong Q1 net profit up 9.3% on higher revenue
Nestle sales growth sputters on US slump, vitamin snags
Hermes Q1 sales jump 17% on strong China demand
Cordlife’s independent auditor to retire after issuing disclaimer of opinion on FY2023 financials
Cutting the cord?: Events leading up to Cordlife’s MOH suspension and arrests of its directors, ex-group CEO